Burosumab (Crysvita)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses burosumab (Crysvita) injection, 10 mg/mL, 20 mg/mL, and 30 mg/mL, solution for injection, subcutaneous injection. Indication: For the treatment of X-linked hypophosphatemia in adult and pediatric patients aged 6 months and older.